Android app Apple app link

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

By Yahoo! Finance   |   1 month ago
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

The Phase 3 ICONIC LEAD subgroup analysis shows promising efficacy of icotrokinra in treating adolescents with moderate-to-severe plaque psoriasis. This novel therapeutic option offers a favorable safety profile and potential for complete skin clearance, addressing the unique challenges faced by young patients with psoriasis.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.